Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma.

Simple item page
dc.contributor.authorTiwari, B P
dc.contributor.authorJangra, S
dc.contributor.authorNair, N
dc.contributor.authorTongaonkar, H B
dc.contributor.authorBasu, S
dc.date.accessioned2013-01-16T05:19:28Z
dc.date.available2013-01-16T05:19:28Z
dc.date.issued2010-10
dc.description.abstractProstate cancer is one of the most common malignancies of elderly males. Management depends on the accurate estimation of disease both at initial diagnosis and in its subsequent course. In the present study, we evaluated the diagnostic utility of positron emission tomography with 18 F-fluorodeoxyglucose (FDG-PET) in patients having prostate cancer. The findings were compared with the results of bone scan (BS) for the detection of bone metastases. Sixteen patients (age range, 55-83 years) with confirmed diagnosis of prostate cancer were included in the prospective study. Three patients had undergone bilateral orchidectomy, 1 had hormonal therapy, 9 had undergone both, and 3 had no therapy. All the patients underwent wholebody BS and FDG-PET within 1 week. Interpretation of BS and FDG-PET were performed qualitatively. Osseous abnormalities detected by both methods were compared. Involvement of the disease in other sites as seen on FDG-PET was also noted. BS detected 197 osseous lesions, whereas FDG-PET could detect 97 (49%) bone lesions. However, in 3 patients without any prior therapeutic intervention, FDG-PET results were superior or equivalent to that of BS. FDG-PET also detected extensive involvement of the disease in the bone marrow in 4 patients, lymph node metastases at various sites in 8, liver metastases in 2, and lung metastases in 1 patient. FDG-PET could demonstrate less number of osseous metastases in comparison with BSs, but the results have to be interpreted in the background of prior treatment administered and the tumor biology of the lesion. It is evident that FDG-PET could detect the unknown soft tissue involvement of the disease with good sensitivity, which might play an important role in the management of prostate cancer. Overall, in the absence of novel PET tracers, both skeletal scintigraphy and FDG-PET imaging can play a complimentary role in the management of prostate cancer.en_US
dc.identifier.citationTiwari B P, Jangra S, Nair N, Tongaonkar H B, Basu S. Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma. Indian Journal of Cancer. 2010 Oct-Dec; 47(4): 385-390.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/144376
dc.language.isoenen_US
dc.source.urihttps://www.indianjcancer.com/article.asp?issn=0019-509X;year=2010;volume=47;issue=4;spage=385;epage=390;aulast=Tiwarien_US
dc.subjectBone scanen_US
dc.subjectFDG-PETen_US
dc.subjectprostate carcinomaen_US
dc.subjectscintigraphyen_US
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshBone Neoplasms --radionuclide imaging
dc.subject.meshFluorodeoxyglucose F18 --diagnostic use
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPositron-Emission Tomography
dc.subject.meshProstatic Neoplasms --radionuclide imaging
dc.subject.meshRadionuclide Imaging --methods
dc.subject.meshRadiopharmaceuticals --diagnostic use
dc.subject.meshTechnetium --diagnostic use
dc.titleComplimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijc2010v47n4p385.pdf
Size:
719.01 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Cancer